In the realm of food safety, where every decision can be a matter of life and death, I find myself reflecting on the myriad questions that have shaped my career. As I prepare for meetings with industry leaders and educators, I can't help but ponder the critical issues that persist, despite the advancements made over the past three decades. The food safety fight, an ongoing battle, demands constant vigilance and a reevaluation of our strategies. Here, I offer my insights and opinions on some of the most pressing questions, drawing from my extensive experience in this field.
Operational Changes: A Matter of Priorities
One question that resonates deeply is: If you could force one operational change across the industry, what would it be, and why aren't we already doing it? My answer is straightforward: Test your products, and when they test positive, don't ship them. This may seem like a no-brainer, but it's astonishing how often businesses prioritize profit over safety. The ability to trace a sick child back to a specific lot number is a game-changer, thanks to whole genome sequencing. It's time for companies to embrace this technology and make a conscious decision to prioritize safety over speed to market.
Transparency: A Double-Edged Sword
Another question that demands attention is: When an outbreak hits, does fast transparency actually reduce what we can recover against companies, or does it just help us sleep at night? In my opinion, it genuinely reduces the potential for recovery. Companies that act swiftly and transparently, taking responsibility for their actions, often settle cases quietly and for a fraction of what a cover-up would cost. The truth is, doing the right thing is also the cheapest thing, and it's time for companies to recognize this.
Third-Party Audits: A Misplaced Priority
I've long believed that third-party audits are an area where we might be overspending relative to the real risk. I've seen plants earn superior ratings days before they caused harm, as seen in cases like Peanut Corporation and Jensen Farms cantaloupes. These audits can provide a false sense of security, and the industry needs to reevaluate its priorities. Instead, companies should invest in unannounced testing and addressing the issues they uncover.
Litigation: A Remote Possibility
The idea of litigating myself out of business is an intriguing concept, but it's a long shot. In theory, it's possible, given the known pathogens and interventions. However, in practice, it's unlikely I'll live to see it. The goal keeps me honest, and I remain committed to the cause, even if I don't reach the ultimate goal.
Prior Conduct vs. Severity of Injury
When evaluating a case, how much weight does prior conduct carry versus the severity of the injury? Severity and causation are crucial, but prior knowledge and conduct play a significant role in determining the outcome. A company that made a mistake once might be given a chance, while a company with a history of negligence should face the consequences. It's a delicate balance, and it's my job to ensure justice is served.
Allocating Resources: A Matter of Life and Death
If we had one additional appropriation to direct between FDA, FSIS, and CDC, where would the marginal dollar save the most lives? My answer is clear: Surveillance and inspection. The FDA's inspection capacity is woefully inadequate, and we can't act on outbreaks we can't see. By investing in these areas, we can detect and prevent outbreaks, saving countless lives.
Salmonella: A Case for Change
Salmonella still isn't an adulterant in most poultry. What's the cleanest path to changing that? The answer lies in declaring outbreak-associated, high-load Salmonella scenarios as adulterants in raw poultry, just as we did for Big Six non-O157 STECs in beef in 2012. It's time for the agency to take action, or Congress should step in. The objection to Salmonella being a naturally occurring contaminant is disingenuous, and it's time to prioritize public health over convenience.
Adverse-Event Reporting: A System in Crisis
The ByHeart outbreak highlighted the gaps in adverse-event reporting. What specific gap failed those families, and what's the narrowest fix? The system is voluntary, slow, and structurally blind. We need mandatory, time-bound reporting of serious adverse events, with real teeth, and the FDA should have the authority to act on early signals. These are babies, and the reporting system should be their voice, not a whisper.
Raw Milk: A Matter of Freedom and Responsibility
On raw milk, is meaningful labeling enough, or does this need something with more teeth? I believe labeling alone isn't sufficient. Strong, plain-language warnings should be the minimum. The personal-freedom argument collapses when you consider the toddlers who end up on dialysis with hemolytic uremic syndrome. Freedom ends where a child's kidneys begin.
FOIA Exemption 4: A Barrier to Transparency
Agencies often invoke the deliberative-process exemption to withhold outbreak records. Where's the line? Genuine pre-decisional deliberation is protectable, but the facts aren't deliberative. Companies also hide behind FOIA Exemption 4 to keep plant records out of the public's hands. Exemption 4 is a real issue, and it's time to reevaluate how we protect trade secrets versus public health.
In conclusion, the food safety fight is far from over, and these questions demand our attention. As an expert in this field, I offer my insights and opinions, hoping to spark a broader conversation and drive positive change. It's time for the industry to embrace transparency, prioritize safety, and reevaluate its priorities. The lives of countless individuals depend on it.
